Strategy to induce apoptosis and circumvent resistance in chronic lymphocytic leukaemia

被引:17
作者
Chen, Rong [1 ]
Plunkett, William [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
关键词
chronic lymphocytic leukaemia; therapy; transcription inhibitor; translation inhibitor; cyclin-dependent kinase; anti-apoptotic proteins; CYCLIN-DEPENDENT KINASE; SMALL-MOLECULE INHIBITOR; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; CHRONIC MYELOGENOUS LEUKEMIA; CYC202; R-ROSCOVITINE; RNA-POLYMERASE-II; MYC MESSENGER-RNA; B-CELL LYMPHOMA; IN-VITRO; DOWN-REGULATION;
D O I
10.1016/j.beha.2010.01.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic lymphocytic leukaemia (CLL) is characterised by the dependence on the overexpression of anti-apoptotic proteins to maintain their survival. Based on this biological context, a strategy for CLL therapy was proposed using inhibitors of transcription and translation to transiently reduce the short-lived survival proteins and induce cell death. This includes inhibitors of the cyclin-dependent kinases required for the activation of RNA polymerase II, as well as homoharringtonine and silvestrol, the natural compounds that inhibit translation. As their actions are independent of p53 or ataxia telangiectasia mutated (ATM) function, agents that act by such mechanisms are promising to overcome resistance to current CLL therapy. Further, the combination of inhibitors of transcription and translation, together with other approaches that interfere with the function of anti-apoptotic proteins, may initiate synergistic killing in CLL. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:155 / 166
页数:12
相关论文
共 101 条
[81]   IAP proteins: Blocking the road to death's door [J].
Salvesen, GS ;
Duckett, CS .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (06) :401-410
[82]   A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours [J].
Scott, Edwina N. ;
Thomas, Anne L. ;
Molife, L. Rhoda ;
Ahmed, Samreen ;
Blagden, Sarah ;
Fong, Peter C. ;
Kowal, Kristin ;
McCoy, Candice ;
Wiesinger, Herbert ;
Steward, Will ;
De Bono, Johann .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (02) :425-429
[83]   Mechanisms of action of flavopiridol [J].
Sedlacek, HH .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 38 (02) :139-170
[84]  
SHAPIRO G, 2003, P AM SOC CLIN ONCOL, V22
[85]   Cyclin-dependent kinase pathways as targets for cancer treatment [J].
Shapiro, GI .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (11) :1770-1783
[86]   Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709 [J].
Siemeister, G. ;
Luecking, U. ;
Wagner, C. ;
Detjen, K. ;
Mc Coy, C. ;
Bosslet, Klaus .
BIOMEDICINE & PHARMACOTHERAPY, 2006, 60 (06) :269-272
[87]   Cyclin D1 splice variants - Differential effects on localization, RB phosphorylation, and cellular transformation [J].
Solomon, DA ;
Wang, Y ;
Fox, SR ;
Lambeck, TC ;
Giesting, S ;
Lan, Z ;
Senderowicz, AM ;
Knudsen, ES .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (32) :30339-30347
[88]   The nucleolin targeting aptamer AS1411 destabilizes bcl-2 messenger RNA in human breast cancer cells [J].
Soundararajan, Sridharan ;
Chen, Weiwei ;
Spicer, Eleanor K. ;
Courtenay-Luck, Nigel ;
Fernandes, Daniel J. .
CANCER RESEARCH, 2008, 68 (07) :2358-2365
[89]   Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines [J].
Squires, Matthew S. ;
Feltell, Ruth E. ;
Wallis, Nicola G. ;
Lewis, E. Jonathan ;
Smith, Donna-Michelle ;
Cross, David M. ;
Lyons, John F. ;
Thompson, Neil T. .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (02) :324-332
[90]   Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia [J].
Tam, Constantine S. ;
O'Brien, Susan ;
Wierda, William ;
Kantarjian, Hagop ;
Wen, Sijin ;
Do, Kim-Anh ;
Thomas, Deborah A. ;
Cortes, Jorge ;
Lerner, Susan ;
Keating, Michael J. .
BLOOD, 2008, 112 (04) :975-980